Animal models to investigate the effects of inflammation on remyelination in multiple sclerosis

Marjan Gharagozloo, Jackson W. Mace, Peter A. CalabresiFrontiers in Molecular Neuroscience 2022 · DOI

This review article, published in Frontiers in Molecular Neuroscience, provides a comprehensive overview of the animal models used to study Multiple Sclerosis (MS), specifically focusing on the complex interplay between inflammation and the failure of the central nervous system (CNS) to repair its own myelin.

TL;DR

While current MS drugs effectively dampen the "fire" of inflammation, they fail to help the brain "rebuild" lost myelin. This paper reviews how researchers are moving beyond simple models to "combinatorial" animal models that simulate how a persistent inflammatory environment actively blocks the brain's natural repair mechanisms.

What Problem Does This Paper Address?

Multiple Sclerosis is a two-part tragedy: first, the immune system attacks the protective myelin sheath around axons (demyelination); second, the brain’s natural repair crew (oligodendrocyte progenitor cells, or OPCs) often fails to finish the job (remyelination failure).

The "translational gap" in MS research is significant. Many drugs that promote repair in a petri dish or in simple toxin-based animal models fail in human clinical trials. The authors argue this is because standard models are too specialized:

  1. EAE (Experimental Autoimmune Encephalomyelitis): Excellent for studying the immune attack but poor for studying repair because lesions occur unpredictably in the spinal cord.
  2. Toxin Models (e.g., Cuprizone): Excellent for studying repair in a "clean" environment but lack the complex, messy inflammation found in actual MS patients.

The challenge is creating a model that captures both the inflammatory "smoke" and the "reconstruction" process simultaneously.

Methods

The paper categorizes and evaluates several classes of animal models, highlighting the shift toward combinatorial approaches:

  • Toxin-Induced Models: Using chemicals like Cuprizone or Lysolecithin to kill oligodendrocytes. These are standard for studying the "inside-out" hypothesis (where primary CNS damage triggers a secondary immune response).
  • Genetic Ablation: Using the Diphtheria Toxin (DTA/DTR) system to selectively kill oligodendrocytes via specific promoters (like Plp1), allowing for precise timing of demyelination.
  • Combinatorial Models (The "New Standard"):
    • ATCup (Adoptive Transfer Cuprizone): Researchers induce demyelination with cuprizone and then "add back" specific inflammatory cells (like Th17 cells) to see exactly how they stall repair.
  • Cup/EAE: Combining toxin-induced damage with active immunization to create forebrain lesions that more closely resemble human MS pathology.
  • Inducible Genetic Models: Using systems like the tetracycline-off (tTA) system to "turn on" inflammatory cytokines (like IFNγ) in the brain at specific times to observe their inhibitory effects on repair.

Datasets

As a review article, this paper does not introduce a new raw dataset but synthesizes decades of findings from established models. It references key transgenic mouse lines including:

  • Plp1-CreERT;ROSA26-eGFP: For lineage tracing of oligodendrocytes.
  • GFAP/tTA;TRE/IFNγ: For studying the effects of astrocyte-produced Interferon-gamma.
  • PDGFRα-CreER x Rosa26-YFP: For fate-mapping the progenitor cells (OPCs) responsible for repair.

Key Insights and Ideas

  • Inflammation as a Roadblock: Inflammation isn't just the cause of the damage; it is a potent inhibitor of the cure. The paper highlights that cytokines like IFNγ and IL-17 directly polarize OPCs into an "immune-like" state (iOPCs), preventing them from maturing into myelin-making cells.
  • The "Inside-Out" vs. "Outside-In" Debate: The authors discuss whether MS starts with an immune attack from the blood (outside-in) or if dying brain cells trigger the immune system (inside-out). Recent models suggest that chronic oligodendrocyte death alone can eventually trigger a full-blown autoimmune response.
  • Astrocyte Toxicity: Beyond just forming "scars," reactive astrocytes in an inflammatory environment secrete "toxic lipoparticles" (containing saturated lipids) that are actively lethal to the cells trying to repair the brain.

Key Results

The review summarizes quantitative findings from various combinatorial studies:

  • Th17 cells were shown to significantly suppress endogenous remyelination in the ATCup model by targeting OPCs directly.
  • IFNγ expression in the CNS was found to promote MHC class I expression on OPCs, making them targets for cytotoxic T-cell killing, thereby depleting the "repair crew."
  • Chronic Cuprizone models (12 weeks of exposure) result in permanent axonal loss and CNS atrophy, providing a better (though still imperfect) proxy for progressive MS than acute models.

Limitations and Future Work

The authors acknowledge that no single animal model perfectly replicates human MS.

  • The Aging Factor: Most studies use young mice, whereas MS is a chronic disease that interacts with the aging brain. Future models need to incorporate aged animals.
  • Chronic vs. Acute: Most models are still relatively short-term. Replicating the decades-long "smoldering" inflammation of progressive MS remains a hurdle.
  • Clinical Translation: The authors suggest that using combinatorial models (like ATCup) to screen drugs will likely lead to a higher success rate in human trials because these models force a drug to work in the presence of inhibitory inflammation.

Summary updated

Abstract

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system (CNS). In people with MS, impaired remyelination and axonal loss lead to debilitating long-term neurologic deficits. Current MS disease-modifying drugs mainly target peripheral immune cells and have demonstrated little efficacy for neuroprotection or promoting repair. To elucidate the pathological mechanisms and test therapeutic interventions, multiple animal models have been developed to recapitulate specific aspects of MS pathology, particularly the acute inflammatory stage. However, there are few animal models that facilitate the study of remyelination in the presence of inflammation, and none fully replicate the biology of chronic demyelination in MS. In this review, we describe the animal models that have provided insight into the mechanisms underlying demyelination, myelin repair, and potential therapeutic targets for remyelination. We highlight the limitations of studying remyelination in toxin-based demyelination models and discuss the combinatorial models that recapitulate the inflammatory microenvironment, which is now recognized to be a major inhibitor of remyelination mechanisms. These models may be useful in identifying novel therapeutics that promote CNS remyelination in inflammatory diseases such as MS.
BibTeX
@inproceedings{gharagozloo2022animal,
  author = {Marjan Gharagozloo and Jackson W. Mace and Peter A. Calabresi},
  title = {{Animal models to investigate the effects of inflammation on remyelination in multiple sclerosis}},
  booktitle = {Frontiers in Molecular Neuroscience},
  year = {2022},
  doi = {10.3389/fnmol.2022.995477},
}
Figure